Posts Tagged ‘Bone loss’

BUSINESSWIRE: The results of phase 2 (there are three) trials of a new drug that reduces testosterone to castrate levels and serum free testosterone to levels lower than orchiectomy or LHRH analogs – without bone loss or hot flashes- are about to be reported in the US. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFO-LINK: A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. READ MORE>

Read Full Post »

URO TODAY: Testicular prostheses that slow-release drugs to combat bone loss in men being treated for advanced prostate cancer, have the potential to restore testes removal as a viable option for testosterone control. READ MORE>

Read Full Post »

NORWAY POST: Alpharadin, a new drug that treats men with hormone-refractory prostate cancer that has spread to the bone, will be developed by a Norwegian cancer therapeutics company and global drugs giant Bayer. READ MORE>

Read Full Post »

CANCER CONSULTANTS.COM: A drug treatment called Bonefos (sodium clodronate) – that blocks the function of the cells which reabsorb bone – reduces the risk of death by 23% in men with metastatic prostate cancer, report UK researchers. READ MORE>

Read Full Post »

NEW ENGLAND JOURNAL OF MEDICINE: A new drug just approved by the FDA for high risk prostate cancer patients suffering bone loss has performed well in a trial.

Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures among men receiving androgen-deprivation therapy for non-metastatic prostate cancer.

Background: Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture.

We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-{kappa}B ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer.

Methods: In this double-blind, multicenter study, we randomly assigned patients to receive denosumab at a dose of 60 mg subcutaneously every 6 months or placebo (734 patients in each group).

The primary end point was percent change in bone mineral density at the lumbar spine at 24 months. Key secondary end points included percent change in bone mineral densities at the femoral neck and total hip at 24 months and at all three sites at 36 months, as well as incidence of new vertebral fractures.

Results: At 24 months, bone mineral density of the lumbar spine had increased by 5.6% in the denosumab group as compared with a loss of 1.0% in the placebo group (P<0.001); significant differences between the two groups were seen at as early as 1 month and sustained through 36 months.

Denosumab therapy was also associated with significant increases in bone mineral density at the total hip, femoral neck, and distal third of the radius at all time points.

Patients who received denosumab had a decreased incidence of new vertebral fractures at 36 months (1.5%, vs. 3.9% with placebo) (relative risk, 0.38; 95% confidence interval, 0.19 to 0.78; P=0.006). Rates of adverse events were similar between the two groups.

Researchers: Matthew R. Smith, M.D., Ph.D., Blair Egerdie, M.D., Narciso Hernández Toriz, M.D., Robert Feldman, M.D., Teuvo L.J. Tammela, M.D., Fred Saad, M.D., Jiri Heracek, M.D., Ph.D., Maciej Szwedowski, M.D., Chunlei Ke, Ph.D., Amy Kupic, M.A., Benjamin Z. Leder, M.D., Carsten Goessl, M.D., for the Denosumab HALT Prostate Cancer Study Group.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: New data published in the New England Journal of Medicine clearly suggests that bone-loss drug denosumab has a significant effect compared to placebo in men with prostate cancer. READ MORE>

Read Full Post »

Older Posts »